FDA advisory panel recommends HIV-preventive Truvada; Depomed gets $1M milestone from Ironwood;

 @FierceBiotech: Preclinical breakthrough: Scientists beat rare skin cancer tumors. Story | Follow @FierceBiotech

 @RyanMFierce: The Indian gov't has launched a probe into its drug regulator after scathing parliamentary report. More | Follow @RyanMFierce

> Radnor, PA-based Polymedix announced that it is no longer enrolling patients in two clinical trials for its anticoagulant reversing agent PMX-60056. The company cited a side effect--reduced blood pressure--in patients as the reason for the discontinued enrollment. Article

> An FDA advisory panel has recommended 19-3 that Gilead's Truvada be approved as a preventive treatment for people at high risk of contracting HIV. The FDA will consider the panel's recommendation when deciding whether or not to approve the drug; the regulator is expected to make its final call by June 15. Release

> Depomed, a specialty pharma company that formulates its products using its proprietary Acuform technology, announced today that it has received a $1 million milestone payment from Ironwood Pharmaceuticals. Depomed licensed its Acuform gastric retentive drug delivery technology to Ironwood for use in a program directed at gastrointestinal afflictions. Release

Pharma News

 @FiercePharma: Bundling dialysis payments, aimed at preventing overuse of anemia meds, promotes underuse instead--NYT. Report | Follow @FiercePharma

> FDA review questions long-term use of bone-building drugs. Article

> FDA advisory panel backs Truvada for HIV prevention. Story

> Merck notches a win in Vioxx litigation. News

Medical Devices New

 @FierceMedDev: A Kensey Nash shareholder, claiming a raw deal, is suing to block the company's $360M sale to DSM. News | Follow @FierceMedDev

> Boston Sci boasts stroke risk reduction for Watchman implant. More

> Ariosa Diagnostics inks deal with LabCorp for prenatal test. Item

> St. Jude Medical: Long-term ICD survival rates higher than with drugs alone. Article

And Finally… PROLOR Biotech announced today the pricing of a previously underwritten IPO; the company is offering 6.5 million shares at $5.00 per share. Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.